|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||54.57 - 54.57|
|52 Week Range||54.57 - 54.57|
|Beta (5Y Monthly)||1.16|
|PE Ratio (TTM)||43.20|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Perrigo Company plc shares slid 3% in premarket trade Thursday, after the company said it's voluntarily recalling albuterol sulfate inhalation aerosols over concerns that some may not dispense properly due to clogging. The Dublin-based maker of over-the-counter and generic health products already halted production and distribution of the aerosols. "Corrective action plans are underway and a definitive timeline for product reintroduction has not been determined at this time," the company said in a statement. Perrigo is expecting to book a charge of $18 million to $22 million in the third quarter relating to the recall, and has not booked any revenue from the product since August. It reiterated its guidance for fiscal 2020 adjusted per-share earnings to range from $3.95 to $4.15, citing strong demand in the consumer self-care Americas business and faster-than-expected recovery in consumer self-care international and base prescription businesses that were hurt by the pandemic. Shares have fallen 3.5% in the year to date, while the S&P 500 has gained 4.8%.
Perrigo Company plc (NYSE; TASE: PRGO) today announced a voluntary U.S. nationwide recall of albuterol sulfate inhalation aerosol to the retail level after previously halting production and distribution. These actions are being taken out of an abundance of caution as a result of complaints that some units may not dispense due to clogging. Perrigo's generic albuterol sulfate inhalation aerosol was developed in partnership with and manufactured by Catalent Pharma Solutions.
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.